financetom
Business
financetom
/
Business
/
Linde's fourth-quarter guidance disappoints on weaker Europe volumes
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Linde's fourth-quarter guidance disappoints on weaker Europe volumes
Oct 31, 2025 9:02 AM

Oct 31 (Reuters) - Linde ( LIN ) on Friday followed a

quarterly earnings beat with a cautious profit outlook for the

rest of the year because of weakness in the European business of

the world's largest industrial gases company.

The U.S.-German group, which supplies gases such as oxygen,

nitrogen and hydrogen to factories and hospitals, forecast its

fourth-quarter adjusted earnings per share at between $4.10 and

$4.20 per share, below analysts' $4.23 mean estimate, according

to LSEG data.

In the third quarter, Linde ( LIN ) reported a 7% rise in its

adjusted earnings per share to $4.21, ahead of analysts' $4.18

estimate, with sales rising 3% to $8.62 billion, broadly in line

with forecast.

However, volume sales fell 3% in Linde's ( LIN ) largest Europe,

Middle East and Africa region, which accounts for 36% of total

sales and CEO Sanjiv Lamba told analysts the company expected

that trend to continue.

The group's New York-listed shares were down 1.8% at

1535 GMT.

The chemical industry has been grappling with weak demand

and high input costs in Europe, and a challenging regulatory

environment has further pressured companies to rethink their

strategies in the region.

Despite its cautious fourth-quarter outlook, Linde ( LIN )

reaffirmed its full-year forecast of growth of between 5% and 6%

in adjusted earnings per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dolly Varden Silver Completes Bought-Deal Public Offering; Down Nearly 5%
Dolly Varden Silver Completes Bought-Deal Public Offering; Down Nearly 5%
Mar 26, 2024
10:52 AM EDT, 03/26/2024 (MT Newswires) -- Dolly Varden Silver Corp. ( DOLLF ) said Tuesday that it has raised gross proceeds of about $15 million by completing its bought deal public offering. Under the offering, Dolly Varden sold about 14.3 million shares on a charitable basis that will qualify as flow-through shares at $1.05 per Charity FT share. The...
United States Steel Says EPA, DOJ Authorize Consent Decree for Clairton Plant Incidents
United States Steel Says EPA, DOJ Authorize Consent Decree for Clairton Plant Incidents
Mar 26, 2024
10:50 AM EDT, 03/26/2024 (MT Newswires) -- United States Steel ( X ) said Tuesday that the US Environmental Protection Agency and the Department of Justice have authorized the consent decree that addressed the Clairton Plant fire in 2018 and power outages in 2019 and 2022. The consent decree with the Allegheny County Health Department, Clean Air Council, and PennEnvironment...
ASGN Unit Wins $120 Million Cybersecurity Contract With Centers for Medicare and Medicaid Services
ASGN Unit Wins $120 Million Cybersecurity Contract With Centers for Medicare and Medicaid Services
Mar 26, 2024
10:50 AM EDT, 03/26/2024 (MT Newswires) -- ASGN's ( ASGN ) ECS brand said Tuesday it has won a $120 million contract with the Department of Health and Human Services to provide cybersecurity services to the Centers for Medicare and Medicaid Services until 2029. The contract was won via ECS subsidiary Iron Vine Security, which began providing managed cybersecurity services...
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency
Mar 26, 2024
10:54 AM EDT, 03/26/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Tuesday that the UK's Medicines and Healthcare Products Regulatory Agency has cleared its clinical trial authorization application for BEAM-302, which is intended for the treatment of alpha-1 antitrypsin deficiency, an inherited genetic disorder. The company said it intends to roll out a phase 1/2 trial of BEAM-302...
Copyright 2023-2026 - www.financetom.com All Rights Reserved